

- (2006) Dynamic changes in dopaminergic neurotransmission induced by a low concentration of bisphenol-A in neurones and astrocytes. *J Neuroendocrinol*, 18: 434-444.
- Mizuo, K., Narita, M., Miyagawa, K., Okuno, E. and Suzuki, T. (2004a) Prenatal and neonatal exposure to bisphenol-A affects the morphine-induced rewarding effect and hyperlocomotion in mice. *Neurosci Lett*, 356: 95-98.
- Mizuo, K., Narita, M., Yoshida, T. and Suzuki, T. (2004b) Functional changes in dopamine D3 receptors by prenatal and neonatal exposure to an endocrine disruptor bisphenol-A in mice. *Addict Biol*, 9: 19-25.
- Narita, M., Mizoguchi, H., Suzuki, T., Dun, N. J., Imai, S., Yajima, Y., Nagase, H. and Tseng, L. F. (2001) Enhanced μ -opioid responses in the spinal cord of mice lacking protein kinase C γ isoform. *J Biol Chem*, 276: 15409-15414.
- Narita, M., Miyatake, M., Shibasaki, M., Tsuda, M., Koizumi, S., Yajima, Y., Inoue, K. and Suzuki, T. (2005) Long-lasting change in brain dynamics induced by methamphetamine: Enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. *J Neurochem*, 93: 1383-1392.
- Narita, M., Miyagawa, K., Mizuo, K., Yoshida, T. and Suzuki, T. (2006) Prenatal and neonatal exposure to low-dose of bisphenol-A enhance the morphine-induced hyperlocomotion and rewarding effect. *Neurosci Lett*, 402: 249-252.
- Olea, N., Pulgar, R., Perez, P., Olea-Serrano, F., Rivas, A., Novillo-Fertrell, A., Pedraza, V., Soto, A. M. and Sonnenschein, C. (1996) Estrogenicity of resin-based composites and sealants used in dentistry. *Environ Health Perspect*, 104: 298-305.
- Pasti, L., Volterra, A., Pozzan, T. and Carmignoto, G. (1997) Intracellular calcium oscillations in astrocytes: A highly plastic, bidirectional form of communication between neurons and astrocytes in situ. *J Neurosci*, 17: 7817-7830.
- Suzuki, T., Mizuo, K., Nakazawa, H., Funae, Y., Fushiki, S., Fukushima, S., Shirai, T. and Narita, M. (2003) Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: Enhancement of the methamphetamine-induced abuse state. *Neuroscience*, 117: 639-644.
- Tang, X. C., McFarland, K., Cagle, S. and Kalivas, P. W. (2005) Cocaine-induced reinstatement requires endogenous stimulation of μ -opioid receptors in the ventral pallidum. *J Neurosci*, 25: 4512-4520.
- Volkel, W., Colnot, T., Csanady, G. A., Filser, J. G. and Dekant, W. (2002) Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. *Chem Res Toxicol*, 15: 1281-1287.
- Zetterstrom, R. H., Solomin, L., Mitsiadis, T., Olson, L. and Perlmann, T. (1996) Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. *Mol Endocrinol*, 10: 1656-1666.

Changes in central dopaminergic systems and morphine reward by prenatal and neonatal exposure to bisphenol-A in mice: evidence for the importance of exposure period

Minoru Narita, Kazuya Miyagawa, Keisuke Mizuo, Takuya Yoshida & Tsutomu Suzuki

Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Japan

ABSTRACT

Bisphenol-A has been extensively evaluated for toxicity in a variety of tests as the most common environmental endocrine disruptors. In a previous study, we reported that exposure to bisphenol-A affects the development of the central dopaminergic system in the mouse limbic area. The present study was undertaken to investigate the relationship between the developmental toxicity of bisphenol-A and its exposure period. The exposure to bisphenol-A during either organogenesis or lactation, but not implantation and parturition, significantly enhanced the morphine-induced hyperlocomotion and rewarding effects. Furthermore, exposure to bisphenol-A during either organogenesis or lactation also produced an up-regulation of dopamine receptor function to activate G-protein in the mouse limbic forebrain. These results indicate that both organogenesis and lactation are more sensitive to the bisphenol-A-induced developmental neuronal toxicology than any other periods. In conclusion, the present data suggest that the organogenesis and lactation are the most important period to cause the alternation of dopaminergic system by bisphenol-A exposure in the mouse.

Keywords Bisphenol-A, endocrine disruptor, exposure periods, hyperlocomotion, morphine, rewarding effect.

Correspondence to: Minoru Narita, Tsutomu Suzuki, Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawaku, Tokyo 142-8501, Japan. E-mail: narita@hoshi.ac.jp; suzuki@hoshi.ac.jp

INTRODUCTION

Many aquatic ecosystems might be polluted with bisphenol-A, a possible endocrine disruptor that is widely used as a monomer for the production of plastics, resins and coatings (Staples *et al.* 1998). The global mass production is 1.7 million tons in the world and 0.35 million tons in Japan (reported by the BPA Safety Committee of Japanese Manufactures 2002) and the chemical is widely used all over the world. Bisphenol-A is a global environmental contaminant, used in polycarbonate plastics, and is reported to display weak estrogenic activity both *in vitro* and *in vivo* (Krishnan *et al.* 1993; Ashby & Tinwell 1998; Gould *et al.* 1998; Kuiper *et al.* 1998). The bioactivity of bisphenol-A is 1000–15 000 times lower than 17 β -estradiol.

It has been reported that administration of bisphenol-A to pregnant mice on gestation days at a dose that is within the range typical of the environmental exposure of

humans produces significant changes in the postnatal growth rate and brings on early puberty in these mice (Howdeshell *et al.* 1999). Bisphenol-A also inhibits the differentiation of oligodendrocyte precursor cells induced by exposure to thyroid hormone (Seiwa *et al.* 2004). These results support the idea that bisphenol-A may cause toxicity in the developmental process.

Recently, we have demonstrated that prenatal and neonatal exposure to bisphenol-A markedly enhances the rewarding effects induced by drugs of abuse, such as methamphetamine (Suzuki *et al.* 2003) and morphine (Mizuo *et al.* 2004a). In addition, prenatal and neonatal exposure to bisphenol-A enhances central dopamine D₁ receptor function (Suzuki *et al.* 2003) and attenuates dopamine D₂ receptor function (Mizuo *et al.* 2004b) in mice. These findings indicate that exposure to bisphenol-A may cause alterations in dopaminergic neurotransmission in the central nervous system resulting in the enhancement of drug reward. The aim of the present

study was to further investigate the relationship between the effects of bisphenol-A on dopamine-related behaviors and the bisphenol-A exposure period, and to determine the most sensitive period in prenatal and neonatal exposure to bisphenol-A in mice.

MATERIALS AND METHODS

The present study was conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University, as adopted by the Committee on Animal Research of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports, Science and Technology of Japan. All efforts were made to minimize the number of animals used and their suffering.

Animals

All experiments were performed using male ddY mice that had been prenatally and neonatally exposed to bisphenol-A (Wako Pure Chemical Industries Ltd, Osaka, Japan). Adult female mice were chronically treated with bisphenol-A-admixed powder food containing 0 (control), 2 mg of bisphenol-A/g of food during the period of implantation [I-2; embryonic day (ED) 0–7], organogenesis (O-2; ED 7–14), parturition (P-2; ED 14–20) and lactation (L-2; postnatal day 0–20). Their pups were prenatally and neonatally exposed to the respective concentration of bisphenol-A from their mothers. During the treatment with bisphenol-A, animals did not show weight loss or disrupted maternal behaviors. In addition, the pups did not show weight loss or decrease of birth rate. All experiments used mice aged 7–9 weeks.

Place conditioning

Place conditioning was conducted as previously described (Suzuki *et al.* 1991; Narita, Funada & Suzuki 2001). The apparatus was a shuttle box (15 × 30 × 15 cm: width × length × height), which was made of an acrylic resin board and divided into two equal-sized compartments. One compartment is white with a textured floor, and the other is black with a smooth floor to create equally preferred compartments. For conditioning, mice were confined to one compartment after drug injections and to the other compartment after saline injection. The order of the injection (drug or vehicle) and compartment (white or black) was counterbalanced across subjects. Conditioning sessions (3 days for morphine, 3 days for saline) were conducted once daily for 6 days. Immediately after subcutaneous injection (s.c.) injection of morphine (1 mg/kg), animals were placed in one compartment for 1 hour. On alternate days, animals receiving vehicle were placed in the other compartment for 1 hour. On day seven, tests of conditioning were performed as follows. The partition separating the two

compartments was raised to 7 cm above the floor, and a neutral platform was inserted along the seam separating the compartments. The mice were not treated with either morphine or saline, and then placed on the platform. The time spent in each compartment during a 900-second session was then recorded automatically using an infra-red beam sensor (KN-80, Natsume Seisakusyo Co., Tokyo, Japan). The preference for drug-paired place was shown as a mean difference between the time spent during the drug-conditioning compartment and saline-conditioning compartment. All sessions were conducted under conditions of dim illumination (28-lux lamp) and white masking noise. In this study, we used 6–16 mice.

Measurement of locomotor activity

The locomotor activity of mice was measured by an ambulometer as described previously (Narita *et al.* 1993). Briefly, a mouse was placed in a tilting-type round activity cage 20 cm in diameter and 19 cm high. Any slight tilt of the activity cage, which was caused by horizontal movement of the mouse, was detected by three microswitches. Total activity counts were automatically recorded for 3 hours following the injection of saline (10 ml/kg, s.c.) or morphine (10 mg/kg, s.c.). In this study, we used 9–10 mice.

[³⁵S]GTPγS binding assay

In the membrane preparation, mice were killed by decapitation and the limbic forebrain was then dissected as described previously (Narita *et al.* 2001). The limbic forebrain was rapidly excised at 4°C, and the tissues were homogenized using a Potter–Elvehjem tissue grinder with a Teflon pestle in 20 volumes (w/v) of ice-cold Tris-Mg²⁺ buffer containing 50 mM Tris-HCl (pH 7.4), MgCl₂ and 1 mM ethylene glycol-bis-(beta-aminoethyl ether)-N,N'-tetra-acetic acid (EGTA) for the [³⁵S]GTPγS binding assay. The homogenate was centrifuged at 4°C for 10 minutes at 48 000 × g. The pellet was resuspended in [³⁵S]GTPγS binding assay buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl₂, 1 mM EGTA and 100 mM NaCl and centrifuged at 4°C for 10 minutes at 48 000 × g. The resultant pellet was resuspended in [³⁵S]GTPγS binding assay buffer and stored at –70°C until used. The membrane homogenate (3–8 μg of protein/assay) was incubated at 25°C for 2 hours in 1 ml of assay buffer with various concentrations of dopamine, 30 μM guanosine-5'-diphosphate (GDP) and 50 pM [³⁵S]GTPγS (specific activity, 1000 Ci/mmol; Amersham, Arlington Heights, IL, USA). The reaction was terminated by filtration using a Brandle cell harvester and Whatman GF/B glass filters pre-soaked in 50 mM Tris-HCl (pH 7.4) and 5 mM MgCl₂ at 4°C for 2 hours. Filters were then washed three times with 5 ml of ice-cold Tris-HCl buffer (pH 7.4), transferred to scintillation counting vials containing 0.5 ml of

Soluene-350 and 4 ml of Hionic Fluor, equilibrated for 12 hours, and the radioactivity in the samples was determined with a liquid scintillation analyzer. Non-specific binding was measured in the presence of 10 μM unlabeled GTP γS . Comparable results were obtained from at least three independent sets of experiments.

Statistical analysis

Data represent the mean counts with SEM. Statistical analyses were performed using one-way ANOVA with Bonferroni/Dunnett's test.

RESULTS

Enhancement of morphine-induced hyperlocomotion in mice exposed to bisphenol-A during the organogenesis or lactation period

Treatment with 10 mg/kg (s.c.) morphine produced a locomotor-enhancing effect in all groups. In both O-2 and L-2 mice, but not I-2 and P-2, the hyperlocomotion induced by morphine was dramatically potentiated as compared with that in control ($P < 0.05$ versus control, Fig. 1).

Enhancement of morphine-induced rewarding effect in mice exposed to bisphenol-A during the organogenesis or lactation period

At the dose of 1 mg/kg, morphine produced neither place preference nor place aversion in control, I-2 and P-2 mice. However, treatment with 1 mg/kg morphine produced a significant place preference in both O-2 and L-2 ($P < 0.05$ versus control, Fig. 2).

The dopamine-induced G-protein activation in the limbic forebrain of mice exposed to bisphenol-A during the organogenesis or lactation period

Dopamine (0.1–10 μM) produced a concentration-dependent increase in [^{35}S]GTP γS binding to membranes from the limbic forebrain including the nucleus accumbens of control, I-2, O-2, P-2 and L-2 mice. It should be noted that the stimulation of [^{35}S]GTP γS binding induced by dopamine was markedly potentiated in O-2 and L-2 mice (Fig. 3).

DISCUSSION

Drug addiction is a pathological behavior characterized by compulsive drug seeking and drug ingestion despite severe adverse consequences. The place-conditioning paradigm has become the most frequently used method to evaluate the motivational properties and its use has been reported more frequently than the self-administration paradigm (Suzuki 1996).




Figure 1 Enhancement of the morphine-induced hyperlocomotion in mice exposed to bisphenol-A during organogenesis or lactation. (a) Time-course changes in the morphine-induced hyperlocomotion in control and bisphenol-A-treated (I-2, O-2, P-2 and L-2) mice (I = implantation, O = organogenesis, P = parturition, L = lactation). Each point represents the mean activity counts for 10 minutes with SEM of 9–10 mice. O-2 (triangle), $F_{(1,299)} = 11.4$, $P < 0.01$ versus control (open square); L-2 (filled square), $F_{(1,299)} = 4.1$, not significant. (b) Total activity in the morphine-induced hyperlocomotion in control and bisphenol-A-treated (I-2, O-2, P-2 and L-2) mice. Mice exposed to bisphenol-A in each period are shown as I-2, O-2, P-2 and L-2 groups. Each column represents the mean total activity counts for 180 minutes with SEM of 9–10 mice. * $P < 0.05$ versus control. s.c. = subcutaneous injection

Many studies have suggested that the mesolimbic dopaminergic system that projects from the ventral tegmental area (VTA) to the nucleus accumbens is critical for the initiation of opioid reinforcement and hyperlocomotion (Stinus *et al.* 1986; Wise & Rompre 1989; Koob 1992). Either [D-Ala²,N-Me-Phe⁴,Gly⁵-ol]enkephalin (DAMGO)- or morphine-induced place preference can be blocked by dopamine receptor antagonists (Phillips, LePiane & Fibiger 1983; Shippenberg, Bals-Kubik & Herz 1993). In addition, hyperlocomotion induced by morphine can be blocked by treatment with dopamine receptor antagonists in the nucleus accumbens (Maldonado *et al.* 1990; Funada, Suzuki & Misawa 1994). These




Figure 2 Enhancement of the morphine-induced rewarding effect in mice exposed to bisphenol-A during organogenesis or lactation. (Inner) Dose–response for the morphine-induced place preference in control mice (## $P < 0.01$ versus saline-treated mice). (Outer) Mice exposed to bisphenol-A in each period are shown as I-2, O-2, P-2 and L-2 groups (I = implantation, O = organogenesis, P = parturition, L = lactation). Each column represents the mean conditioning score with SEM of 6–16 mice. * $P < 0.05$ versus control. s.c. = subcutaneous injection

findings indicate that the dopamine-containing neuron of the midbrain VTA, which has a high density of μ -opioid receptors, plays a critical role in the rewarding effects and hyperlocomotion by μ -opioid receptor agonists. In terms of dopamine receptor involvement at the terminal site of the mesolimbic dopamine system, the rewarding effects of abused drug have been shown to be mediated by dopamine D_1 receptors (Shippenberg *et al.* 1993; Suzuki *et al.* 1993). In addition, the dopamine D_3 receptor cloned by Sokoloff *et al.* (1990) has been characterized extensively. The dopamine D_3 receptor shows a distinct distribution in limbic areas of the brain, including the nucleus accumbens and olfactory tubercle (Sokoloff *et al.* 1990). Several pharmacological studies with dopamine D_3 receptor-preferring agonists such as 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) suggest that the dopamine D_3 receptor regulates the inhibitory effect to produce hyperlocomotion in rodents (Suzuki *et al.* 1995; De Boer *et al.* 1997). In addition, we found that the morphine-induced rewarding effect and hyperlocomotion were markedly enhanced in mice lacking the dopamine D_3 receptor gene (Narita *et al.* 2003). These findings suggest that the dopamine D_3 receptor plays a critical role in mediating drug-induced effects on dopamine neurotransmission.

In the previous study, we reported that prenatal and neonatal exposure to bisphenol-A enhances the rewarding effect of drugs of abuse, which is associated with the up-regulation of central dopamine D_1 receptor function and down-regulation of the functional dopamine D_3 receptors in mice (Suzuki *et al.* 2003; Mizuo *et al.*




Figure 3 Comparison of the stimulation of [35 S]GTP γ S binding to membranes from the limbic forebrain by dopamine between control and bisphenol-A-treated mice. Membranes were incubated with [35 S]GTP γ S (50 μ M) and guanosine-5'-diphosphate (GDP) (30 μ M) with dopamine. The data are shown as the percentage of basal [35 S]GTP γ S binding measured in the presence of GDP and absence of dopamine. Mice exposed to bisphenol-A in each period are shown as I-2, O-2, P-2 and L-2 groups (I = implantation, O = organogenesis, P = parturition, L = lactation). Each column represents the mean with SEM of three independent experiments. * $P < 0.05$, ** $P < 0.01$ versus control

2004a,b). In the present study, we investigated the relationship between these neuronal changes and the exposure period for bisphenol-A. The exposure to bisphenol-A during either organogenesis or lactation significantly enhanced the morphine-induced hyperlocomotion and rewarding effect. These findings suggest that prenatal and neonatal, especially organogenetical and lactational, exposure to bisphenol-A leads to the supersensitivity of drugs of abuse-induced pharmacological actions.

Morphine has been shown to indirectly activate dopamine neurons in the VTA as a consequence of inhibiting non-dopaminergic neurons, presumably γ -aminobutyric acid-containing neurons, leading to the increased dopamine release in the nucleus accumbens. In a previous study, we reported that prenatal and neonatal exposure to bisphenol-A failed to enhance μ -opioid receptor-mediated G-protein activation by morphine in the lower midbrain (Mizuo *et al.* 2004a). We further showed that the expression of μ -opioid receptor mRNA was not changed by chronic bisphenol-A treatment, suggesting that μ -opioid receptor function is unaffected in this region (Mizuo *et al.* 2004a). Therefore, we next investigated the influence of prenatal and neonatal exposure to bisphenol-A in mesolimbic dopaminergic function using [35 S]GTP γ S binding assay. The exposure to bisphenol-A during either organogenesis or lactation also produced an up-regulation of dopamine receptor function to activate G-protein in the mouse limbic forebrain. These

results indicate that either organogenesis or lactation is more sensitive to the bisphenol-A-induced neuronal toxicity than any other periods.

Recently, several investigations have provided evidence that the treatment of adult animals with bisphenol-A could not affect the reproductive function and social behaviors (Cagen *et al.* 1999; Farabollini *et al.* 2002). We have already confirmed that acute administration of bisphenol-A with adult mice could not affect the dopamine-related behaviors (data not shown). On the other hand, several investigations clarified the behavioral abnormalities by prenatal and neonatal exposure to bisphenol-A. These findings indicate that prenatal and neonatal exposure to bisphenol-A may cause the neuronal toxicity specifically in the developmental process. In the present study, we focused on the relationship between these developmental changes and the exposure period for bisphenol-A. The exposure to bisphenol-A during either organogenesis or lactation significantly enhanced the morphine-induced hyperlocomotion and rewarding effect. Furthermore, the exposure to bisphenol-A during either organogenesis or lactation also produced an up-regulation of dopamine receptor function to activate G-protein in the mouse limbic forebrain. These results indicate that either organogenesis or lactation is more sensitive to the bisphenol-A-induced developmental toxicity than any other periods.

Generally, in cerebral development, it is well known that the proliferation, differentiation or migration of nerve cells and glia cells are carried out most briskly at organogenesis (Temple 2001). Additionally, the functional development of the central nervous system, synaptogenesis and the construction of the nerve network are carried out most briskly at lactation (Temple 2001). Therefore, these reports strongly support our present results that these are most sensitive periods for the influence of bisphenol-A exposure in the development of the central nervous system. Our findings suggest the idea that exposure during organogenesis to bisphenol-A could affect the differentiation or migration of neuronal stem cells. Additionally, lactation exposure to bisphenol-A affects the functional development of the central nervous system including synaptogenesis and the construction of the neuronal network.

Taken together, the present data may explain that although the treatment of adult animals with bisphenol-A could not affect the reproductive function and social behaviors, the prenatal and neonatal exposure, especially either organogenesis or lactation, to bisphenol-A induced developmental neuronal toxicity in the midbrain of rodents. Our findings warn that exposure to bisphenol-A during either organogenesis or lactation may predispose their children to the development of dopamine-related disorders.

Acknowledgements

This work was supported in part by grants from the Ministry of Health, Labour and Welfare, and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- Ashby J, Tinwell H (1998) Uterotrophic activity of bisphenol A in the immature rat. *Environ Health Perspect* 106:719–720.
- BPA Safety Committee of Japanese Manufactures (2002) [www document] <http://www.bisphenol-a.gr.jp> (accessed on 31 March 2007).
- Cagen SZ, Waechter JM Jr, Dimond SS, Breslin WJ, Butala JH, Jekat FW, Joiner RL, Shiotsuka RN, Veenstra GE, Harris LR (1999) Normal reproductive organ development in CE-1 mice following prenatal exposure to bisphenol A. *Toxicol Sci* 50:36–44.
- De Boer P, Enrico P, Wright J, Wise LD, Timmerman W, Moor E, Dijkstra D, Wikstrom HV, Westerink BH (1997) Characterization of the effect of dopamine D₃ receptor stimulation on locomotion and striatal dopamine levels. *Brain Res* 758:83–91.
- Farabollini F, Porrini S, Della Seta D, Bianchi F, Dessi-Fulgheri F (2002) Effects of perinatal exposure to bisphenol A on sociosexual behavior of female and male rats. *Environ Health Perspect* 110:409–414.
- Funada M, Suzuki T, Misawa M (1994) The role of dopamine D₁-receptors in morphine-induced hyperlocomotion in mice. *Neurosci Lett* 169:1–4.
- Gould JC, Leonard LS, Maness SC, Wagner BL, Conner K, Zacharewski T, Safe S, McDonnell DP, Gaido KW (1998) Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. *Mol Cell Endocrinol* 142:203–214.
- Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenberg JG, vom Saal FS (1999) Exposure to bisphenol A advances puberty. *Nature* 401:763–764.
- Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. *Trends Pharmacol Sci* 13:177–184.
- Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D (1993) Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. *Endocrinology* 132:2279–2286.
- Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology* 139:4252–4263.
- Maldonado R, Dauge V, Feger J, Roques BP (1990) Chronic blockade of D₂ but not D₁ dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by ketorphan, administered in the accumbens in rats. *Neuropharmacology* 29:215–223.
- Mizuo K, Narita M, Miyagawa K, Okuno E, Suzuki T (2004a) Prenatal and neonatal exposure to bisphenol-A affects the morphine-induced rewarding effect and hyperlocomotion in mice. *Neurosci Lett* 356:95–98.
- Mizuo K, Narita M, Yoshida T, Suzuki T (2004b) Functional changes in dopamine D₃ receptors by prenatal and neonatal exposure to an endocrine disruptor bisphenol-A in mice. *Addict Biol* 9:19–25.

- Narita M, Funada M, Suzuki T (2001) Regulations of opioid dependence by opioid receptor types. *Pharmacol Ther* 89:1–15.
- Narita M, Mizuo K, Mizoguchi H, Sakata M, Narita M, Tseng LF, Suzuki T (2003) Molecular evidence for the functional role of dopamine D₃ receptor in the morphine-induced rewarding effect and hyperlocomotion. *J Neurosci* 23:1006–1012.
- Narita M, Takahashi Y, Takamori K, Funada M, Suzuki T, Misawa M, Nagase H (1993) Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice. *Jpn J Pharmacol* 62:15–24.
- Phillips AG, LePiane FG, Fibiger HG (1983) Dopaminergic mediation of reward produced by direct injection of enkephalin into the ventral tegmental area of rat. *Life Sci* 33:2505–2511.
- Seiwa C, Nakahara J, Komiyama T, Katsu Y, Iguchi T, Asou H (2004) Bisphenol A exerts thyroid-hormone-like effects on mouse oligodendrocyte precursor cells. *Neuroendocrinology* 80:21–30.
- Shippenberg TS, Bals-Kubik R, Herz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine and D-1 versus D-2 dopamine receptors. *J Pharmacol Exp Ther* 265:53–59.
- Sokoloff P, Giros B, Martres M-P, Bouthnet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D₃) as a target for neuroleptics. *Nature* 347:146–151.
- Staples CA, Dorn PB, Klecka GM, O'Block ST, Harris LR (1998) A review of the environmental fate, effects, and exposures of bisphenol A. *Chemosphere* 36:2149–2173.
- Stinus L, Nadaud D, Jauregui J, Kelley AE (1986) Chronic treatment with five different neuroleptics elicits behavioral supersensitivity to opiate infusion into the nucleus accumbens. *Biol Psychiatry* 21:34–48.
- Suzuki T (1996) Conditioned place preference in mice. *Methods Find Exp Clin Pharmacol* 18:75–83.
- Suzuki T, Funada M, Narita M, Misawa M, Nagase H (1991) Pertussis toxin abolishes mu- and delta-opioid agonist-induced place preference. *Eur J Pharmacol* 205:85–88.
- Suzuki T, Funada M, Narita M, Misawa M, Nagase H (1993) Morphine-induced place preference in the CXBK mouse: characteristics of m opioid receptor subtypes. *Brain Res* 602:45–52.
- Suzuki T, Maeda J, Funada M, Misawa M (1995) The D₃-receptor agonist (+/-)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. *Neurosci Lett* 187:45–48.
- Suzuki T, Mizuo K, Nakazawa H, Funae Y, Fushiki S, Fukushima S, Shirai T, Narita M (2003) Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D₃ receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state. *Neuroscience* 117:639–644.
- Temple S (2001) The development of neural stem cells. *Nature* 414:112–117.
- Wise RA, Rompre PP (1989) Brain dopamine and reward. *Annu Rev Psychol* 40:191–225.

Prenatal and neonatal exposure to low-dose of bisphenol-A enhance the morphine-induced hyperlocomotion and rewarding effect

Minoru Narita*, Kazuya Miyagawa, Keisuke Mizuo, Takuya Yoshida, Tsutomu Suzuki*

Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawaku, Tokyo 142-8501, Japan

Received 15 January 2006; received in revised form 25 March 2006; accepted 8 April 2006

Abstract

Bisphenol-A has been extensively evaluated for toxicity in a variety of tests as the most common environmental endocrine disruptors. In the previous study, we reported that prenatal and neonatal exposure to high-dose of bisphenol-A affects the development of central dopaminergic system in the mouse limbic area. The present study was then undertaken to investigate whether prenatal and neonatal exposure to lower dose of bisphenol-A could change the morphine-induced several pharmacological actions such as rewarding effect and hyperlocomotion in mice. Prenatal and neonatal exposure to low-dose of bisphenol-A enhanced the morphine-induced hyperlocomotion and rewarding effect. Additionally, the treatment with bisphenol-A produced an up-regulation of dopamine receptor function to activate G-protein in the mouse limbic forebrain, which is thought to play a critical role for hyperlocomotion and rewarding effects by drugs of abuse. These findings suggest that prenatal and neonatal exposure to low-dose of bisphenol-A can potentiate the central dopamine receptor-dependent neurotransmission, resulting in the supersensitivity of the morphine-induced hyperlocomotion and rewarding effects in the mouse.

© 2006 Elsevier Ireland Ltd. All rights reserved.

Keywords: Bisphenol-A; Dopamine; Morphine; Rewarding effect; Hyperlocomotion; Endocrine disruptor

Bisphenol-A is an environmental endocrine-disrupting chemical that affects reproduction in wildlife [4,5]. Bisphenol-A is a monomer of polycarbonate plastics and a constituent of epoxy and polystyrene resins, which are used in the food cans and found as a contaminant not only in the liquid of the preserved foods, but also in the water autoclaved in the cans [1,7]. This chemical is also released from polycarbonate flasks during autoclaving [9]. Moreover, it has been reported that significant amounts of bisphenol-A are detected in the saliva of dental patients treated with fissure sealants [15].

On the endocrine-disrupting chemical problems, the low-dose actions of the endocrine-disrupting chemicals are serious problems. However, little is known about its action on the central nervous system induced by low-dose of bisphenol-A. The aim of the present study was then undertaken to investigate whether prenatal and neonatal exposure to low-dose of bisphenol-A in mice could affect the rewarding effect and locomotor-enhancing effects induced by morphine.

The present studies were conducted in accordance with the Guide for Care and Use of Laboratory Animals adopted by the Committee on Care and Use of Laboratory Animals of Hoshi University School of Pharmacy and Pharmaceutical Sciences, which is accredited by the Ministry of Education, Culture, Sports, Science and Technology of Japan.

All experiments were performed using 7 weeks old male ddY mice (Tokyo Animal Science Co., Tokyo, Japan) that had been prenatally and neonatally exposed to bisphenol-A (Wako Pure Chemical Industries Ltd., Osaka, Japan). Adult female mice (10 weeks old) were chronically treated with bisphenol-A-admixed powder food containing 0 (control), 3×10^{-2} , 3×10^{-1} , 3×10^2 , 2×10^3 μg bisphenol-A/g of food from mating to weaning. Their pups were prenatally and neonatally exposed to the respective concentration of bisphenol-A from their mothers. During the treatment with bisphenol-A, animals did not show weight loss and disruption of maternal behaviors.

The place conditioning paradigm has been known to the method to evaluate the motivational properties as the self-administration paradigm [13,18]. The apparatus was a shuttle box ($15 \times 30 \times 15$ cm: $w \times l \times h$) which was made of acrylic resin board and divided into two equal-sized compartments. One compartment is white with a textured floor, and the other is

* Corresponding authors. Tel.: +81 3 5498 5628; fax: +81 3 5498 5628.
E-mail addresses: narita@hoshi.ac.jp (M. Narita), suzuki@hoshi.ac.jp (T. Suzuki).




Fig. 1. Effect of prenatal and neonatal exposure to a wide range of concentrations of bisphenol-A on the morphine (1 mg/kg, s.c.)-induced rewarding effect in mice. Each column represents the mean conditioning score with S.E.M. of 6–14 mice. * $p < 0.05$, ** $p < 0.01$ vs. morphine-treated control group.

black with a smooth floor to create equally preferred compartments. For conditioning, mice were confined to one compartment after drug injections and to the other compartment after saline injection. The order of the injection (drug or vehicle) and compartment (white or black) was counterbalanced across subjects. A day after these conditioning sessions, the animal is placed in the test apparatus without any confinements. At the dose of 1 mg/kg (s.c.), morphine produced neither place preference nor place aversion in control mice (Fig. 1). However, treatment with 1 mg/kg (s.c.) of morphine produced a significant place preference in the mice chronically treated with low- and high-dose of bisphenol-A, but not middle-dose of bisphenol-A, from mating to weaning (Fig. 1). The locomotor activity of mice was measured by an ambulator as described previously [14]. Briefly, a mouse was placed in a tilting-type round activity cage 20 cm in diameter and 19 cm high. Any slight tilt of the activity cage, which was caused by horizontal movement of the mouse, was detected by three microswitches. Total activity counts were automatically recorded for 3 h following the injection of saline (10 ml/kg, s.c.) or morphine (10 mg/kg, s.c.). Total activity was counted for 3 h after the treatment. Treatment with 10 mg/kg (s.c.) of morphine produced a locomotor-enhancing effect in

all groups (Fig. 2). In mice chronically treated with low- and high-dose of bisphenol-A, but not middle-dose of bisphenol-A, from mating to weaning, the hyperlocomotion induced by morphine was dramatically potentiated as compared to that in control (Fig. 2). These findings suggest that prenatal and neonatal exposure to low- and high-dose of bisphenol-A lead to the supersensitivity of morphine-induced pharmacological actions. It should be mentioned that prenatal and neonatal exposure to bisphenol-A shows the biphasic effect on the supersensitivity of morphine-induced pharmacological actions. Recently, several investigations have provided evidence that the treatment of adult animals with bisphenol-A could not affect the reproductive function and social behaviors [2,3]. We have already confirmed that acute administration of bisphenol-A with adult mice could not affect the dopamine-related behaviors (data not shown). On the other hand, the behavioral abnormalities are induced by prenatal and neonatal exposure to bisphenol-A [11,12,19,20]. These findings indicate that prenatal and neonatal exposure to bisphenol-A may cause the neuronal toxicity specifically in the developmental process. We next investigated the influence of prenatal and neonatal exposure to bisphenol-A in the development of central dopaminergic function using [35 S]GTP γ S binding assay as described previously [20]. In the membrane preparation, mice were killed by decapitation and the limbic forebrain including the nucleus accumbens was then dissected as described previously [17]. The limbic forebrain was rapidly excised at 4 °C, and the tissues were homogenized using a Potter-Elvehjem tissue grinder with a Teflon pestle in 20 volumes (w/v) of ice-cold Tris–Mg $^{2+}$ buffer containing 50 mM Tris–HCl (pH 7.4), MgCl $_2$ and 1 mM EGTA for the [35 S]GTP γ S binding assay. The homogenate was centrifuged at 4 °C for 10 min at 48,000 $\times g$. The pellet was resuspended in ice-cold Tris buffer of [35 S]GTP γ S binding assay buffer containing 50 mM Tris–HCl (pH 7.4), 5 mM MgCl $_2$, 1 mM EGTA, and 100 mM NaCl and centrifuged at 4 °C for 10 min at 48,000 $\times g$. The resultant pellet was resuspended in ice-cold Tris buffer or [35 S]GTP γ S binding assay buffer and stored at –70 °C until used. The membrane homogenate (3–8 μ g protein/assay) was incubated at 25 °C for 2 h in 1 ml of assay buffer with 10 μ M dopamine, 30 μ M guanosine-5'-diphosphate




Fig. 2. Effect of prenatal and neonatal exposure to a wide range of concentrations of bisphenol-A on the morphine-induced hyperlocomotion in mice. (A) Time course changes in the morphine-induced hyperlocomotion in mice. Each point represents the mean activity counts for 10 min with S.E.M. of 5–15 mice. (B) Total locomotor activity of morphine-induced locomotor enhancing effect in mice. Each column represent the mean activity for 180 min with S.E.M. of 5–15 mice. ** $p < 0.01$ vs. saline-treated 3×10^{-2} BPA μ g/g of food-treated group. *** $p < 0.001$ vs. saline-treated 2×10^3 BPA μ g/g of food-treated group. $^{***}p < 0.001$ vs. morphine-treated control group.

(GDP) and 50 pM [35 S]GTP γ S (specific activity, 1000 Ci/mmol; Amersham, Arlington Heights, IL). The reaction was terminated by filtration using a Brandle cell harvester and Whatman GF/B glass filters presoaked in 50 mM Tris–HCl (pH 7.4) and 5 mM MgCl₂ at 4 °C for 2 h. Filters were then washed three times with 5 ml of an ice-cold Tris–HCl buffer (pH 7.4), transferred to scintillation counting vials containing 0.5 ml of Soluene-350 and 4 ml of Hionic Fluor, equilibrated for 12 h and the radioactivity in the samples was determined with a liquid scintillation analyser. Non-specific binding was measured in the presence of 10 μ M unlabeled GTP γ S. Comparable results were obtained from at least three independent sets of experiments. Dopamine (10 μ M) produced an increase in [35 S]GTP γ S binding to membranes from the limbic forebrain including the nucleus accumbens of control mice. Under these conditions, the stimulation of [35 S]GTP γ S binding induced by dopamine was potentiated in mice chronically treated with wide range of concentrations of bisphenol-A from mating to weaning. Especially, the enhancement of the stimulation of [35 S]GTP γ S binding induced by dopamine in mice chronically treated with low- and high dose of bisphenol-A was noted, which suggests that bisphenol-A shows the biphasic effect on the regulation of dopamine receptor function in the limbic forebrain (Fig. 3). Taken together, these findings suggest that the supersensitivity of morphine-induced pharmacological actions following prenatal and neonatal exposure to especially low- and high dose of bisphenol-A may result from a drastic up-regulation of dopamine receptor function in the limbic forebrain (see Fig. 4).

All of data represent the mean counts with S.E.M. Statistical analyses were performed using one-way ANOVA with Bonferroni/Dunnnett's test.

As mentioned above, humans might be orally exposed to bisphenol-A in daily life. In the previous study, we chronically treated female mice with bisphenol-A-admixed powder food containing 2×10^3 μ g of bisphenol-A/g of food, and this




Fig. 3. Comparison of the stimulation of [35 S]GTP γ S binding to membranes from the limbic forebrain by dopamine between control and a wide range of concentrations of bisphenol-A-treated mice. Membranes were incubated with [35 S]GTP γ S (50 pM) and GDP (30 μ M) with dopamine. The data are shown as the percentage of basal [35 S]GTP γ S binding measured in the presence of GDP and absence of dopamine. Each column represents the mean with S.E.M. of three samples. ** $p < 0.01$ vs. control group.




Fig. 4. A schematic drawing of the biphasic effect on the central dopaminergic function by prenatal and neonatal exposure to bisphenol-A. In the previous study, we reported that prenatal and neonatal exposure to high dose ($2-2 \times 10^3$ μ g/g of food) of bisphenol-A change the central dopaminergic function. Here, our findings suggest that supersensitivity of morphine-induced pharmacological actions following prenatal and neonatal exposure to low dose ($3 \times 10^{-2}-3$ μ g/g of food) of bisphenol-A may result from an up-regulation of dopamine receptor function in the limbic forebrain.

enhanced the rewarding effect induced by drugs of abuse in their pups [11,12,20]. Under these conditions, the blood level of bisphenol-A in their pups was approximately 10 ng/ml, which is considered to be more than 30 times higher than the level for healthy human exposure [20]. On the other hand, vom Saal et al. estimated that humans are exposed to bisphenol-A at a dose of 2–20 μ g/kg/day [21]. Based on these reports, we here ascertained the effects of low dose of exposure to bisphenol-A. Adult female mice were chronically treated with bisphenol-A-admixed powder food containing 0 (control), 3×10^{-2} , 3×10^{-1} , 3×10^2 , 5×10^2 , 2×10^3 μ g bisphenol-A/g of food from mating to weaning.

Bisphenol-A and alkylphenols have been reported to have estrogenic activity [8]. Recent molecular studies have suggested the transcriptional activation of the human dopamine D₁ receptor gene by estrogen [10]. Since bisphenol-A has only very weak estrogenic effects [23], it does not seem likely that low dose of bisphenol-A is accompanied by a classical estrogenic activity. It was reported that the binding of bisphenol-A to the non-classical membrane-bound estrogen receptor activates a guanylyl cyclase, protein kinase G and closing K_{ATP} channels [16]. Additionally, low dose of bisphenol-A can activate the transcription factor, cAMP-responsive element binding protein (CREB). Phosphorylated CREB has been shown to be increased after only a 5 min application of bisphenol-A in a calcium-dependent manner [16]. Therefore, the supersensitivity of morphine-induced pharmacological actions caused by prenatal and neonatal exposure to low dose of bisphenol-A may be mediated by non-classical membrane-bound estrogen receptors.

On the other hand, the animal model for hyperactivity was produced by Shaywitz et al., who demonstrated that rat pups treated with 6-hydroxydopamine (6-OHDA) via intracisternal administration at 5 days of age developed increased motor activity caused by the reduction of tyrosine hydroxylase (TH)-sensitive dopamine, leading to cognitive difficulties in shuttle-box learning between 2 and 4 weeks of age [17]. Additionally, Ishido et al. have reported that high dose of bisphenol-A affects the central dopaminergic system, resulting in hyperactivity due most likely to a large reduction TH activity in the midbrain

[6]. Based on these reports, we hypothesize that prenatal and neonatal exposure to high dose of bisphenol-A may cause the dopamine depletion for the limited time period and in turn induce the long-lasting supersensitivity of dopamine receptor-related action following chronic treatment with morphine.

It is very difficult to explain the fact that the prenatal and neonatal exposure to middle-dose of bisphenol-A have only weak effect on the disruption of functional changes in the dopaminergic transmission. Although the mechanisms of the weak effect by the prenatal and neonatal exposure to middle-dose of bisphenol-A remain unclear, one possibility is that the potentiation of the central dopaminergic transmission caused by the prenatal and neonatal exposure to low dose of bisphenol-A can be offset by the middle-dose of bisphenol-A through the negative feedback regulation. It is also likely that prenatal and neonatal exposure to high dose of bisphenol-A may potentiate the dopamine receptor function following a dramatic deletion of TH-sensitive dopamine and/or dysfunction of negative feedback mechanism against dopamine receptor function following the overshooting of its negative feedback.

On the endocrine-disrupting chemical problems, the low dose actions are serious problems. As well as described in the present study, it was recently reported that there were effects caused by exposure to low doses of bisphenol-A on rate of growth and sexual maturation, hormone levels in blood, reproductive organ function, fertility, immune function, enzyme activity, and brain structure, brain chemistry and behavior [22]. Therefore, our findings warn that prenatal and postnatal exposure to low- and high doses of bisphenol-A may dramatically change the neuronal transmission including dopaminergic transmission in the adult brain. This phenomenon could explain the aggravation of the development of dependence on drugs of abuse.

Acknowledgments

This work was supported in part by grants from the Ministry of Health, Labour and Welfare, and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- [1] J.A. Brotons, M.F. Olea-Serrano, M. Villalobos, V. Pedraza, N. Olea, Xenoestrogens released from lacquer coatings in food cans, *Environ. Health Perspect.* 103 (1995) 608–612.
- [2] S.Z. Cagen, J.M. Waechter Jr., S.S. Dimond, W.J. Breslin, J.H. Butala, F.W. Jekat, R.L. Joiner, R.N. Shiotsuka, G.E. Veenstra, L.R. Harris, Normal reproductive organ development in CF-1 mice following prenatal exposure to bisphenol A, *Toxicol. Sci.* 50 (1999) 36–44.
- [3] F. Farabollini, S. Porrini, D. Della Seta, F. Bianchi, F. Dessi-Fulgheri, Effects of perinatal exposure to bisphenol A on sociosexual behavior of female and male rats, *Environ. Health Perspect.* 110 (Suppl. 3) (2002) 409–414.
- [4] D.M. Fry, Reproductive effects in birds exposed to pesticides and industrial chemicals, *Environ. Health Perspect.* 103 (Suppl. 7) (1995) 165–171.
- [5] L.J. Guillette Jr., D.A. Crain, A.A. Rooney, D.B. Pickford, Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife, *Environ. Health Perspect.* 103 (Suppl. 7) (1995) 157–164.
- [6] M. Ishido, Y. Masuo, M. Kunimoto, S. Oka, M. Morita, Bisphenol A causes hyperactivity in the rat concomitantly with impairment of tyrosine hydroxylase immunoreactivity, *J. Neurosci. Res.* 76 (2004) 423–433.
- [7] Y. Kawamura, K. Inoue, H. Nakazawa, T. Yamada, T. Maitani, Cause of bisphenol A migration from cans for drinks and assessment of improved cans, *Shokuhin Eiseigaku Zasshi* 42 (2001) 13–17.
- [8] W. Kloas, I. Lutz, R. Einspanier, Amphibians as a model to study endocrine disruptors: II. Estrogenic activity of environmental chemicals in vitro and in vivo, *Sci. Total Environ.* 225 (1999) 59–68.
- [9] A.V. Krishnan, P. Stathis, S.F. Permeth, L. Tokes, D. Feldman, Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving, *Endocrinology* 132 (1993) 2279–2286.
- [10] S.H. Lee, M.M. Mouradian, Up-regulation of D1A dopamine receptor gene transcription by estrogen, *Mol. Cell Endocrinol.* 156 (1999) 151–157.
- [11] K. Mizuo, M. Narita, K. Miyagawa, E. Okuno, T. Suzuki, Prenatal and neonatal exposure to bisphenol-A affects the morphine-induced rewarding effect and hyperlocomotion in mice, *Neurosci. Lett.* 356 (2004) 95–98.
- [12] K. Mizuo, M. Narita, T. Yoshida, T. Suzuki, Functional changes in dopamine D3 receptors by prenatal and neonatal exposure to an endocrine disruptor bisphenol-A in mice, *Addict. Biol.* 9 (2004) 19–25.
- [13] M. Narita, M. Funada, T. Suzuki, Regulations of opioid dependence by opioid receptor types, *Pharmacol. Ther.* 89 (2001) 1–15.
- [14] M. Narita, Y. Takahashi, K. Takamori, M. Funada, T. Suzuki, M. Misawa, H. Nagase, Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice, *Jpn. J. Pharmacol.* 62 (1993) 15–24.
- [15] N. Olea, R. Pulgar, P. Perez, F. Olea-Serrano, A. Rivas, A. Novillo-Fertrell, V. Pedraza, A.M. Soto, C. Sonnenschein, Estrogenicity of resin-based composites and sealants used in dentistry, *Environ. Health Perspect.* 104 (1996) 298–305.
- [16] I. Quesada, E. Fuentes, M.C. Viso-Leon, B. Soria, C. Ripoll, A. Nadal, Low doses of the endocrine disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate transcription factor CREB, *FASEB J.* 16 (2002) 1671–1673.
- [17] B.A. Shaywitz, R.D. Yager, J.H. Klopfer, Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction, *Science* 191 (1976) 305–308.
- [18] T. Suzuki, M. Funada, M. Narita, M. Misawa, H. Nagase, Pertussis toxin abolishes mu- and delta-opioid agonist-induced place preference, *Eur. J. Pharmacol.* 205 (1991) 85–88.
- [19] T. Suzuki, K. Mizuo, K. Miyagawa, M. Narita, Exposure to bisphenol-A affects the rewarding system in mice, *Nihon Shinkei Seishin Yakurigaku Zasshi* 25 (2005) 125–128.
- [20] T. Suzuki, K. Mizuo, H. Nakazawa, Y. Funae, S. Fushiki, S. Fukushima, T. Shirai, M. Narita, Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state, *Neuroscience* 117 (2003) 639–644.
- [21] F.S. vom Saal, P.S. Cooke, D.L. Buchanan, P. Palanza, K.A. Thayer, S.C. Nagel, S. Parmigiani, W.V. Welshons, A physiologically based approach to the study of bisphenol A and other estrogenic chemicals on the size of reproductive organs, daily sperm production, and behavior, *Toxicol. Ind. Health* 14 (1998) 239–260.
- [22] F.S. vom Saal, C. Hughes, An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment, *Environ. Health Perspect.* 113 (2005) 926–933.
- [23] W.V. Welshons, S.C. Nagel, K.A. Thayer, B.M. Judy, F.S. vom Saal, Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice, *Toxicol. Ind. Health* 15 (1999) 12–25.

Dynamic Changes in Dopaminergic Neurotransmission Induced by a Low Concentration of Bisphenol-A in Neurones and Astrocytes

M. Miyatake, K. Miyagawa, K. Mizuo, M. Narita and T. Suzuki

Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.

Key words: bisphenol-A, neurone, astrocyte, dopamine, 17 β -oestradiol, drug abuse.

Abstract

One of the most common chemicals that behaves as an endocrine disruptor is the compound 4,4'-isopropylidenediphenol, called bisphenol-A (BPA). We previously reported that prenatal and postnatal exposure to BPA potentiated central dopaminergic neurotransmission, resulting in supersensitivity to psychostimulant-induced pharmacological actions. Many recent findings have supported the idea that astrocytes, which are a subpopulation of glial cells, play a critical role in neuronal transmission in the central nervous system. The present study aimed to investigate the role of neurone–astrocyte communication in the enhancement of dopaminergic neurotransmission induced by BPA. We found that treatment of mouse purified astrocytes and neurone/glia cocultures with BPA *in vitro* caused the activation of astrocytes, as detected by a stellate morphology and an increase in levels of glial fibrillary acidic protein. A low concentration of BPA significantly enhanced the Ca²⁺ responses to dopamine in both neurones and astrocytes. Furthermore, a high concentration of BPA markedly induced the activation of caspase-3, which is a marker of neuronal apoptotic cell death in mouse midbrain neurone/glia cocultures. By contrast, treatment with 17 β -oestradiol (E₂) had no such effects. Prenatal and neonatal exposure to BPA led to an enhancement of the dopamine-dependent rewarding effect induced by morphine. These findings provide evidence that BPA alters dopamine responsiveness in neurones and astrocytes and that, at least in part, it may contribute to potentiate the development of psychological dependence on drugs of abuse.

The foetus uses natural hormonal messages that originate in its own hormone system and that of its mother for developmental guidance. Recently, the general public has received alarming reports regarding the reproductive and health hazards of endocrine-disrupting chemicals in the environment. One of the most common endocrine disruptors is the compound 4,4'-isopropylidenediphenol, called bisphenol-A (BPA), which is used in the manufacture of many types of products. These include polycarbonate plastic food storage containers (i.e. baby bottles and water carboys), the lining of food or beverage cans (1, 2), dental composites and sealants and a bioactive bone cement, indicating the potential for human exposure to BPA in daily life.

Our recent studies suggest that exposure to BPA during prenatal and postnatal development has long-lasting effects on central dopaminergic systems linked with behavioural rewarding effects, as well as drug addiction and the reward induced by drugs of abuse (3, 4). The dopamine projection most often linked with a behavioural-rewarding effect is the

mesolimbic dopamine system, which originates from the ventral tegmental area (VTA) and terminates at the nucleus accumbens.

We previously demonstrated that prenatal and neonatal exposure to BPA markedly enhanced the rewarding effects induced by drugs of abuse, such as methamphetamine (5) and morphine (6). We also demonstrated that, in adult mice, prenatal and neonatal exposure to BPA enhanced function mediated by central D₁ receptors, which play a substantial role in the rewarding effect of drugs of abuse (5). These treatments also attenuated dopamine function mediated by the D₃ receptor subtype that contributes to the inhibitory modulation of D₁/D₂ receptor-mediated signalling (7, 8). These findings indicate that exposure to BPA during development alters dopaminergic neurotransmission in the central nervous system (CNS), which results in enhancement of the psychological dependence on drugs of abuse. However, the mechanisms underlying these enduring effects of BPA are unknown.

Correspondence to: Dr Minoru Narita, Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawaku, Tokyo 142-8501, Japan (e-mail: narita@hoshi.ac.jp); Dr Tsutomu Suzuki (e-mail: suzuki@hoshi.ac.jp).

© 2006 The Authors. Journal compilation © 2006 Blackwell Publishing Ltd

Many toxic stimuli activate astrocytes, as determined by morphological changes and by an increase in the levels of glial fibrillary acidic protein (GFAP), which is a marker of astrocytes (9, 10). The activation of astrocytes may control the structural and functional plasticity of synapses in the CNS. However, long-term exposure to drugs of abuse can induce neuronal plasticity (11, 12), and we have shown that treatment of mouse cortical neurone/glia cocultures with drugs of abuse, such as methamphetamine and morphine, caused morphological changes in astrocytes (13). Moreover, treatment with methamphetamine increased the sensitivity of astrocytes to dopamine, which is responsible for the rewarding effects of psychostimulants and opioids (13). Together, these findings indicate that astrocytes may play an important role in the development of dependence on drugs of abuse.

Although BPA may affect dopaminergic signalling in the CNS, little is known about the role of BPA in neurone-astrocyte communication. The present study aimed to clarify the effect of BPA in neurone-glia communication. We used mouse midbrain neurone/glia cocultures and purified astrocytes to determine the effects of BPA in the mesolimbic dopamine system.

Because the sex steroid hormones (oestrogens and androgens) have been shown to exert profound effects on brain differentiation, neural plasticity and central neurotransmission (14, 15) and BPA has an affinity for oestrogen receptors, albeit 1 : 2000 that of 17 β -oestradiol (E₂) (1), we also investigated the effect of E₂ on astrocytic and neuronal responses and the rewarding effect induced by morphine.

Materials and methods

The present studies were conducted in accordance with the Guide for Care and Use of Laboratory Animals adopted by the Committee on Care and Use of Laboratory Animals of Hoshi University School of Pharmacy and Pharmaceutical Sciences, which is accredited by the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Tissue processing

Purified midbrain astrocytes

Midbrains were dissected from ICR mice at postnatal 1 day (Tokyo Laboratory Animals Science, Tokyo, Japan), minced, and treated with trypsin (0.025%; Invitrogen, Grand Island, NY, USA) dissolved in phosphate-buffered saline (PBS) solution containing 0.02% L-cysteine monohydrate (Sigma-Aldrich, St Louis, MO, USA), 0.5% glucose (Wako Pure Chemicals, Osaka, Japan) and 0.02% bovine serum albumin (Wako Pure Chemicals). After enzyme treatment at 37 °C for 15 min, the cells were dispersed by gentle trituration, collected and centrifuged (20 min, 1000 g). After centrifugation, cells were plated in a flask (75 cm² culture flask; Corning Inc., Corning, NY, USA). Seven days after seeding in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 5% precolostrum newborn calf serum (FBS, Invitrogen), 5% heat-inactivated (56 °C, 30 min) horse serum (HS, Invitrogen), 10 U/ml penicillin and 10 μ g/ml streptomycin in a humidified atmosphere of 95% air and 5% CO₂ at 37 °C, the flask was shaken for 12 h at 37 °C to remove nonastrocytic cells. Seven days after seeding, the cells were seeded at a density of 1×10^5 cells/cm², and maintained for 7 days in DMEM supplemented with 5% FBS, 5% HS, 10 U/ml penicillin and 10⁻⁵ g/ml streptomycin in a humidified atmosphere of 95% air and 5% CO₂ at 37 °C.

Midbrain neurone/glia cocultures

Midbrains were obtained from newborn ICR mice at postnatal 1 day, minced, and treated with papain (9 U/ml; Worthington Biochemical, Lakewood, NJ, USA) dissolved in PBS solution containing 0.02% L-cysteine monohydrate,

0.5% glucose and 0.02% bovine serum albumin. After enzyme treatment at 37 °C for 15 min, the cells were dispersed by gentle trituration, collected and centrifuged (10 min, 1000 g). The cells were then seeded at a density of 2×10^6 cells/cm². The cells were maintained for 7 days in DMEM supplemented with 10% FBS, 10 U/ml penicillin and 10 μ g/ml streptomycin. Eight days after seeding, the cells were treated with drugs. In this culture condition, NeuN-positive neurones are surrounded by astrocytes (16).

Drug treatment and immunohistochemistry

Eight days after seeding, *in vitro*, the cells were treated with either normal medium or medium containing bisphenol A (BPA; 10 fM to 1 μ M; Wako Pure Chemicals) or 1,3,5[10]-estratriene-3,17 β -diol (E₂, 10 fM to 1 μ M; Sigma-Aldrich) for 24 h. To explore role for steroid hormone receptors in mediating the effects of BPA (1 pM or 1 μ M, 24 h), cells were pretreated with either an oestrogen receptor antagonist 7 α ,17 β -[9]-(4,4,5,5,5-pentafluoropentyl)sulfinyl-nonyl]estra-1,3,5(10)-triene-3,17-diol (ICI182,780; 100 nM, 1 μ M or 2 μ M; Tocris-Cookson, Ellisville, MO, USA), an oestrogen receptor agonist/antagonist tamoxifen (100 nM, 1 μ M or 10 μ M; Sigma-Aldrich), a progesterone receptor antagonist mifepristone (100 nM, 1 μ M or 10 μ M; Sigma-Aldrich) or an androgen receptor antagonist flutamide (100 nM, 1 μ M or 10 μ M; Sigma-Aldrich) for 24 h. Cells were then treated with normal medium or BPA (1 pM, 1 nM) with or without these steroid hormone receptor ligands for an additional 24 h. Glial cells were then identified by immunofluorescence using mouse anti-glia fibrillary acidic protein antibody (GFAP, dilution 1 : 1000; Chemicon Inc., Temecula, CA, U.S.A.), rabbit anti-GFAP (dilution 1 : 1000, Chemicon) or mouse anti-neuronal nuclei (Neu-N) antibody (dilution 1 : 1000, Chemicon) followed by incubation with Alexa 488-conjugated goat anti-mouse IgG (dilution 1 : 4000), Alexa 488-conjugated goat anti-rabbit IgG (dilution 1 : 4000) or Alexa 546-conjugated goat anti-mouse IgG (dilution 1 : 4000). Images were collected using a Radiance 2000 laser-scanning microscope (Radiance 2000; Bio-Rad, Carlsbad, CA, USA).

The intensity of GFAP-like immunoreactivity was measured with a computer-assisted system (NIH Image, Bethesda MD, USA). The upper and lower threshold intensity ranges were adjusted to encompass and match the immunoreactivity to provide an image with immunoreactive material appearing in black pixels, and nonimmunoreactive material as white pixels. The area and intensity of pixels within the threshold value representing immunoreactivity were calculated. We randomly chose 10 areas (80 \times 80 pixels) for calculation of GFAP-like immunoreactivity in each image (512 \times 512 pixels). The experiments were repeatedly performed by at least three independent culture preparations. The intensity of GFAP-like immunoreactivity was expressed as a percent increase (mean \pm SEM) with respect to that in control cells, which were seeded on the same plate.

To evaluate the apoptotic neuronal cell death, mouse midbrain neurone/glia cocultures were treated with normal medium, BPA (1 pM, 1 nM or 1 μ M) or E₂ (1 pM, 1 nM or 1 μ M) for 24 h. The cells were then identified by immunofluorescence, using rabbit-anticleaved caspase-3 antibody (dilution 1 : 100; Cell Signaling Technology Inc., Beverly, MA, USA), followed by incubation with Alexa 488 conjugated goat anti-rabbit IgG (dilution 1 : 10000). Images were collected using a Radiance 2000 laser-scanning microscope.

Confocal Ca²⁺ imaging

Confocal Ca²⁺ imaging was conducted as previously described (13, 16). Mouse midbrain neurone/glia cocultures or purified astrocytes were incubated for 24 h with normal medium or medium containing BPA (1 pM, 1 nM or 1 μ M). Cells were then loaded with 10 μ M fluo-3 acetoxymethyl ester (Dojindo Molecular Technologies, Kumamoto, Japan) during a 90-min incubation at room temperature. After a further 20–30 min of de-esterification with the acetoxymethyl ester, the cells which seeded on coverslips were mounted on a microscope equipped with a confocal Ca²⁺ imaging system (Radiance 2000). Fluo-3 was excited with the 488-nm line of an argon-ion laser and the emitted fluorescence was collected at wavelengths > 515 nm, and average baseline fluorescence (F₀) of each cell was calculated. To compensate for the uneven distribution of fluo-3, self-ratios were calculated (ratio: R_s = F/F₀). The amplitude was determined by subtracting the average of baseline fluorescence ratio (F_{basal}/F₀) from the maximum of fluorescence ratio after a drug treatment (F_{max}/F₀). Dopamine (1, 10 or 100 μ M; Sigma-Aldrich) was perfused via a plastic tube for 30 s at 5 ml/min at room temperature in cultured cortical neurones or astrocytes followed by superfusion of basal salt solution (BSS,

pH 7.4) containing 150 mM of NaCl, 5 mM of KCl, 1.8 mM of CaCl₂, 1.2 mM of MgCl₂, 25 mM of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid and 10 mM of D-glucose.

Prenatal and neonatal exposure to BPA

All experiments were performed using male ddY mice (7 weeks old) (Tokyo Laboratory Animals Science) that had been indirectly exposed prenatally and neonatally to BPA, administered to their mothers.

Mice were orally administered either olive oil (control; 0.1 mg/kg), BPA (3 µg/kg/day or 200 mg/kg/day) dissolved in olive oil (Wako Pure Chemicals) or E₂ (3 µg/kg/day) through the stomach sonde. Female mice (10 weeks old) were orally treated with these chemicals three times a day (08.00, 14.00 and 20.00 h): from mating to weaning. Therefore, these chemicals were administered during pregnancy (20 days) and lactation (21 days, total 41 days).

Place conditioning

The place-conditioning procedure has been used to evaluate the motivation properties, such as rewarding or aversive effects, of drugs in adult rodents (17). Place conditioning was conducted as previously described (5, 6). The apparatus was a shuttle box (15 × 30 × 15 cm: w × l × h), which was made of acrylic resin board and divided into two equal-sized compartments. One compartment is white with a textured floor, and the other is black with a smooth floor to create equally preferred compartments. For conditioning, groups of mice (seven mice in a group) were confined to one compartment after morphine injections (morphine-paired side) and to the other compartment after saline injection (saline-paired side). The order of the injection (drug or vehicle) and compartment (white or black) was counterbalanced across subjects. Conditioning sessions (3 days for morphine, 3 days for saline) were conducted once daily for 6 days. Immediately after s.c. injection of morphine (1 mg/kg), animals were placed in one compartment for 1 h. On alternate days, animals receiving the vehicle were placed in the other compartment for 1 h. On day 7, tests of conditioning were performed. The partition separating the two compartments was raised to 7 cm above the floor, and a neutral platform was inserted along the seam separating the compartments. The mice were not treated with either morphine or saline, and then placed on the platform. The time spent in each compartment during a 900-s session was then recorded automatically using an infrared beam sensor (KN-80, Natsume Seisakusyo Co., Tokyo, Japan). All sessions were conducted under conditions of dim illumination (28 lux lamp) and white masking noise.

Statistical analysis

Data for GFAP-like immunoreactivity and confocal Ca²⁺ imaging are presented as the mean ± SEM. The statistical significance of differences between the groups were assessed by one-way analysis of variance (ANOVA) followed by Student's t-test.

Conditioning scores for each mouse were obtained by subtracting the cumulative time spent in the saline-paired side from that in the morphine-paired side, and are expressed as means ± SEM. Statistical analysis for the place conditioning study was conducted using one-way ANOVA followed by Bonferroni/Dunnnett's test.

Results

BPA, but not E₂, causes the activation of astrocytes

To ascertain the effect of BPA in mouse purified midbrain astrocytes, we performed immunohistochemical staining with a

polyclonal antibody for GFAP. The results showed a biphasic response. Mouse midbrain purified astrocytes were treated with either normal medium or BPA (BPA: 10 fM, 100 fM, 1 pM, 10 pM, 1 nM, 10 nM, 100 nM, 1 µM) for 24 h. Treatment with BPA (100 fM, 1 pM, 10 pM, 10 nM, 100 nM or 1 µM) for 24 h caused a robust activation of mouse purified midbrain astrocytes, as detected by a stellate morphology and an increase in the levels of GFAP-like immunoreactivity (P < 0.001 versus control cells) (Fig. 1A,B). On the other hand, treatment with the mid-range doses of BPA (10 fM, 100 pM, 1 nM) for 24 h failed to produce morphological changes in mouse purified midbrain astrocytes (Fig. 1A,B).

Unlike BPA, treatment with E₂ (10 fM to 1 µM, 24 h) failed to produce morphological changes in midbrain astrocytes at all concentrations tested (Fig. 1C,D).

We next explored the effect of BPA on mouse midbrain neurone/glia cocultures. In this culture system, numerous glial cells, especially astrocytes, surround neurones. Mouse midbrain neurone/glia cocultures were treated with either normal medium or BPA (BPA: 10 fM to 1 µM) for 24 h. In neurone/glia cocultures, BPA caused biphasic activations of astrocytes. Treatment with BPA (100 fM, 1 pM, 10 pM, 100 nM or 1 µM, 24 h) caused a robust activation of astrocytes in midbrain neurone/glia cocultures (*P < 0.05, **P < 0.01, ***P < 0.001 versus control cells) (Fig. 2A,B), whereas treatment with BPA (10 fM, 100 pM, 1 nM or 10 nM, 24 h) failed to produce an increase in GFAP-like immunoreactivity in mouse midbrain neurone/glia cocultures. E₂ (10 fM to 1 µM) failed to produce an increase in GFAP-like immunoreactivity in mouse midbrain neurone/glia cocultures at any doses tested (Fig. 2C,D).

Enhancement of dopamine-induced Ca²⁺ responses by BPA





Dopamine (1–100 µM) produced a transient increase in the intracellular Ca²⁺ concentration in mouse purified midbrain astrocytes (Fig. 3). The Ca²⁺ responses to dopamine (100 µM) in astrocytes were significantly enhanced by pretreatment with a low concentration of BPA (1 pM, 24 h, **P < 0.01 versus control cells) (Fig. 3). By contrast, treatment with a high concentration of BPA (1 nM or 1 µM, 24 h) had no effect on the Ca²⁺ responses to dopamine in mouse purified midbrain astrocytes (Fig. 3).

Using immunocytochemical methods shown in Fig. 4(A) according to the study described previously (16), Neu-N-positive neurones are surrounded by GFAP-positive astrocytes in mixed neurone/glia cocultures. On the basis of morphological appearance, neurone-like cells were selected for the Ca²⁺ imaging studies. Under these criteria, dopamine (1–100 µM) produced a transient increase in the intracellular

FIG. 1. Treatment with bisphenol-A (BPA) for 24 h caused biphasic astrocytic activation in mouse purified midbrain astrocytes. (A) Mouse purified midbrain astrocytes were treated with normal medium or BPA (1 pM to 1 µM). The cells were stained with a polyclonal antibody to glial fibrillary acidic protein (GFAP). (B) Mouse purified midbrain astrocytes were treated with normal medium or BPA (10 fM to 1 µM) for 24 h and stained with a polyclonal antibody to GFAP. The intensity of GFAP-immunoreactivity from ten areas in each image was measured using NIH Image. The level of GFAP-like immunoreactivity is expressed as a percent increase (mean ± SEM) with respect to that in control cells. The experiments were repeatedly performed by at least three independent culture preparations. **P < 0.001, ***P < 0.001 versus control cells. (C) Mouse purified midbrain astrocytes were treated with normal medium or 17β-oestradiol (E₂, 1 pM to 1 µM). The cells were stained with a polyclonal antibody to GFAP. (D) Mouse purified midbrain astrocytes were treated with normal medium or E₂ (10 fM to 1 µM) for 24 h and stained with a polyclonal antibody to GFAP. The intensity of GFAP-immunoreactivity from ten areas in each image was measured using NIH Image. The level of GFAP-like immunoreactivity is expressed as a percent increase (mean ± SEM) with respect to that in control cells. The experiments were repeatedly performed by at least three independent culture preparations.

Ca²⁺ concentration in cultured midbrain neurone-like cells (Fig. 4B,C). These Ca²⁺ responses were significantly enhanced by treatment with a low concentration of BPA (1 pM, 24 h,

*P < 0.05, **P < 0.01, ***P < 0.001 versus control cells) (Fig. 4B,C). Treatment with a high concentration of BPA (1 nM, 24 h) had no effect on the Ca²⁺ response to any



concentrations of dopamine, whereas the highest concentration of BPA (1 μM) suppressed the Ca^{2+} response to 100 μM dopamine (** $P < 0.001$ versus control cells) (Fig. 4B,C).

Effects of steroid hormone antagonists on the activation of astrocytes induced by BPA

To explore the involvement of steroid hormone receptor-dependent signalling in the activation of astrocytes, we next investigated whether steroid hormone antagonists could affect the BPA-induced increase in GFAP expression in midbrain astrocyte or neurone/glia cultures. The highly selective oestrogen receptor antagonist ICI182,780 (100 nM, 1 μM , 2 μM) was administered as pretreatment (24 h) and cotreatment (24 h) with BPA (1 pM, 1 μM) in both mouse purified midbrain astrocyte and neurone/glia cocultures. ICI182,780 failed to attenuate the activation of astrocytes induced by BPA (1 pM or 1 μM) (Fig. 5). Pretreatment (24 h) and cotreatment (24 h) with either the oestradiol receptor agonist/antagonist tamoxifen (100 nM, 1 μM or 10 μM), the progesterone receptor antagonist mifepristone (100 nM, 1 μM or 10 μM) or the androgen receptor antagonist flutamide (100 nM, 1 μM or 10 μM) failed to affect the activation of astrocytes induced by BPA (1 pM, 1 μM) in both mouse purified midbrain astrocytes (Fig. 6A–C) and neurone/glia cocultures (Fig. 6D–F). These results suggest that activation of astrocytes by BSA was not mediated via oestrogen receptors, progesterone receptors or androgen.

BPA-induced neuronal cell death

We next investigated whether *in vitro* treatment with either BPA or E_2 could induce neuronal cell death. Treatment with a high concentration of BPA (1 μM , 24 h) in mouse midbrain neurone/glia cocultures caused the robust activation of caspase-3, which is a marker of neuronal cell death (Fig. 7). Unlike BPA, a high concentration of E_2 failed to produce caspase-3 activation (Fig. 7).

Enhancement of morphine-induced rewarding effect in mice prenatally and neonatally exposed to BPA

Morphine modulates several physiological processes including a rewarding effect by stimulating opioid receptors. We previously reported that chronic treatment with morphine (3–5 mg/kg, s.c.) produced a robust place preference in mice (6, 8). However, chronic treatment with a low dose of morphine (1 mg/kg, s.c.) produced neither place preference nor place aversion in control mice (Fig. 8). On the other hand, treatment with 1 mg/kg of morphine produced a

significant place preference in mice whose mothers had been exposed to BPA at a dose of 200 mg/kg/day ($*P < 0.05$ versus control group) (Fig. 8). Treatment with morphine at 1 mg/kg also produced a significant place preference in offspring of mothers chronically treated with BPA at a dose of 3 $\mu\text{g}/\text{kg}/\text{day}$ ($*P < 0.05$ versus control group) (Fig. 8). By contrast, treatment with morphine at 1 mg/kg failed to produce a place preference in offspring of mothers that had been chronically treated with E_2 (3 $\mu\text{g}/\text{kg}/\text{day}$) (Fig. 8).

Discussion

A growing body of evidence suggests that astrocytes are important modulators of synaptic transmission. Astrocytes can respond to neurotransmitters released within the synapse by generating elevations in intracellular Ca^{2+} concentration and release glutamate and/or ATP that signal back to neurones (18, 19). Therefore, it is worthwhile to determine the effects of BPA on astrocytes. In the present study, we investigated the dopaminergic changes in neurones and astrocytes induced by BPA.

We show here for the first time that *in vitro* treatment with BPA caused morphological changes in GFAP-positive astrocytes. In addition, this effect of BPA was biphasic: treatment with 1 pM or 1 μM of BPA caused the robust activation of astrocytes, whereas treatment with 1 nM of BPA had no detectable effect on the morphology of astrocytes.

Inoue *et al.* (20) previously reported that the concentration of BPA was 0.32 ng/ml (approximately 1.4 pM) in normal human serum. Accordingly, it seems likely that 1 μM of BPA is higher than is commonly found in the environment. On the other hand, the amount of BPA that humans are exposed to results in the exposure of astrocytes to concentrations greater than 1 pM.





Neurones and astrocytes respond to various and chemical stimuli, including neurotransmitters, neuromodulators and hormones, with an increase in the intracellular Ca^{2+} concentration. These Ca^{2+} responses result from the co-ordinated activity of several molecular cascades responsible for Ca^{2+} movement into or out of the cytoplasm by way of either the extracellular space or intracellular stores. We have demonstrated that the dopamine-induced Ca^{2+} responses in mixed cultures of neurones and astrocytes were significantly enhanced by treatment with BPA (1 pM, 24 h). These findings strongly support the idea that the enhancement of Ca^{2+} responses to dopamine induced by BPA could lead to an increase in the excitability of central dopaminergic neurotransmission.

It has been reported that the stimulation of dopamine D_1 receptor increased the intracellular Ca^{2+} concentration via

Fig. 2. Treatment with bisphenol-A (BPA) for 24 h caused biphasic astrocytic activation in mouse midbrain neurone/glia cocultures. (A) Mouse midbrain neurone/glia cocultures were treated with normal medium or BPA (1 pM to 1 μM). The cells were stained with a polyclonal antibody to glial fibrillary acidic protein (GFAP). (B) Mouse midbrain neurone/glia cocultures were treated with normal medium or BPA (10 fM to 1 μM) for 24 h and stained with a polyclonal antibody to GFAP. The intensity of GFAP-immunoreactivity was measured using NIH Image. The level of GFAP-like immunoreactivity from ten areas in each image is expressed as a percent increase (mean \pm SEM) with respect to that in control cells. ** $P < 0.001$, *** $P < 0.001$ versus control cells. The experiments were repeatedly performed by at least three independent culture preparations. (C) Mouse midbrain neurone/glia cocultures were treated with normal medium or 17 β -oestradiol (E_2 , 1 pM to 1 μM). The cells were stained with a polyclonal antibody to GFAP. (D) Mouse midbrain neurone/glia cocultures were treated with normal medium or E_2 (10 fM to 1 μM) for 24 h and stained with a polyclonal antibody to GFAP. The intensity of GFAP-immunoreactivity was measured using NIH Image. The level of GFAP-like immunoreactivity is expressed as a percent increase (mean \pm SEM) with respect to that in control cells.

activation of the phospholipase C-inositol-1,4,5-triphosphate signalling pathway (21, 22). Dopamine-induced Ca^{2+} responses are also modulated by dopamine D_2 receptor (23,

24). On the other hand, dopamine D_3 receptor normally coexists with dopamine D_1 and D_2 receptors (25, 26), which contributes to the inhibitory modulation of dopamine D_1



and/or D₂ receptor-mediated signalling (7). We previously reported that prenatal and postnatal exposure to BPA (2 mg/g of mother's food) enhanced central dopamine D₁ receptor function (5) and attenuated dopamine D₃ receptor function in mice (27). Thus, the present data suggest that treatment with 1 pM of BPA may enhance dopamine D₁ receptor function and/or attenuate dopamine D₃ receptor function, resulting in enhancement of the dopamine-induced Ca²⁺ response in neurones and astrocytes.

In the present study, we observed morphological changes in astrocytes by treatment with either 1 pM or 1 μM of BPA. We also found a difference between 1 pM and 1 μM of BPA: treatment with BPA (1 pM) in midbrain neurone/glia cocultures clearly enhanced dopamine-induced Ca²⁺ responses in neurones, whereas treatment with BPA (1 μM) decreased dopamine-induced Ca²⁺ responses in neurones. Treatment with a high concentration of BPA markedly induced neuronal cell death in midbrain neurone/glia cocultures. Thus, these data suggest that a high concentration of BPA may lead to a dynamic change in the neurone-glia network, resulting in neurotoxicity.




Fig. 3. The Ca²⁺ response to dopamine in astrocytes was significantly enhanced by treatment with a low concentration of bisphenol-A (BPA). (A) Traces show a typical increase in the intracellular Ca²⁺ concentration evoked by dopamine (1–100 μM) in control or BPA (1 pM, 1 nM or 1 μM) treated astrocytes. (B) The Ca²⁺ responses to dopamine (1–100 μM) in control and BPA (1 pM, 1 nM or 1 μM) treated astrocytes are summarised. Data represent the mean ± SEM of 27–63 cells. **P < 0.01 versus control cells.




Fig. 4. The Ca²⁺ response to dopamine in neurones was significantly enhanced by treatment with a low concentration of bisphenol-A (BPA). (A) Mouse neurone/glia cocultures were stained with a mouse antibody to anti-neuronal nuclei (Neu-N) (red) and a rabbit antibody to glial fibrillary acidic protein (green). Arrow heads show Neu-N-positive neurones, which we used as cultures neurones for the Ca²⁺ imaging studies. (B) Traces show a typical increase in the intracellular Ca²⁺ concentration in control evoked by dopamine (1–100 μM) or BPA (1 pM, 1 nM or 1 μM) treated neurones. (C) The Ca²⁺ responses to dopamine (1, 10, 100 μM) in control and BPA (1 pM, 1 nM or 1 μM) treated neurones are summarised. Data represent the mean ± SEM of 27–63 cells. *P < 0.05, **P < 0.01, ***P < 0.001 versus control cells.

Similar to other drugs of abuse, the μ-opioid receptor agonist morphine acts as a rewarding stimulus when administered to animals (28). For example, rodents have been shown to intravenously self-administer morphine rather than saline when given a choice (29). Furthermore, μ-opioid receptor agonists can lower the electric current threshold for intracranial electrical self-stimulation, which indicates that opioids can facilitate the central reward mechanism itself. These positive motivational actions of opioids are indicative of their rewarding properties, and are considered to be fundamental for their ability to produce psychological dependence in humans (28).

As mentioned above, humans might be orally exposed to BPA in daily life. In a previous study, we chronically treated pregnant and lactating female mice with BPA-admixed powder food containing 2 mg of BPA/g of food, and this enhanced the development of rewarding effects induced by drugs of abuse in their adult offspring (5, 6). Under these conditions, mother mice received approximately 200 mg/kg/day of BPA. In addition, the blood level of BPA in their pups was approximately 10 ng/ml, which is considered to be more than 30-fold higher than the level for healthy human exposure (5). On the other hand, vom Saal *et al.* (30) estimated that humans are exposed to BPA at a dose of 2–20 µg/kg/day. Based on these reports, we ascertained the effects of oral exposure to BPA. A group of mother mice were orally administered BPA at a dose of 3 µg/kg/day, which is considered to be a suitable dose to reflect environmental exposure to BPA. Another group of mother mice were orally administered BPA at a dose of 200 mg/kg/day, which is considered to be higher than the environmental exposure to BPA. We also investigated the effect of prenatal

and neonatal exposure to E₂ (3 µg/kg/day) to compare its effects with those of BPA. Their pups, which were prenatally and postnatally exposed to BPA, were used in the place preference studies.

One of the most important aspects of the present study was that *in vivo* prenatal and neonatal exposure to BPA (3 µg or 200 mg/kg/day administered to pregnant and lactating dams) clearly enhanced the rewarding effect of morphine in mice. Although BPA at 200 mg/kg/day may be higher than the environmental exposure, BPA may be found in the environment at a level equivalent to 3 µg/kg/day. As mentioned above, *in vitro* experiments indicate that the enhancement of Ca²⁺ responses to dopamine induced by BPA could lead to an increase in the excitability of central dopaminergic neurotransmission in both neurones and astrocytes. These findings suggest that the enhancement of dopaminergic transmission in neurones and astrocytes induced by BPA may, at least in part, lead to enhancement of the development of psychological dependence on morphine.

BPA can modulate gene transcription and numerous biological changes via oestrogenic receptors (1, 31, 32). It has been reported that equal doses of BPA and E₂ could activate the transcription factor cAMP-responsive element binding protein (CREB) via nonclassical oestrogen receptor, resulting in the transcriptional activation of CREB-responsive genes (33). On the other hand, obvious differences between BPA and E₂ have also been reported. For example, E₂ at 10 nM reduced the duration of Ca²⁺ oscillations in mouse oocytes, whereas concentrations of BPA as high as 100 µM were necessary for similar inhibition (34). It has been reported that E₂ inhibits the astrocytic uptake of glutamate, which is the most important excitatory neurotransmitter in the CNS, whereas BPA has no such effect (35). Taken together, these observations suggest that BPA and E₂ may be coupled to different signalling cascades in the CNS.

Astrocytes are among of the most important target cells for E₂. Astrocytes express all types of oestrogen receptors during development and in the adult brain (35–37). However, in the present study, neither the oestrogen receptor antagonist ICI182,780 nor the oestrogen receptor agonist/antagonist tamoxifen failed to block the activation of astrocytes induced by BPA. The progesterone receptor antagonist mifepristone and the androgen receptor antagonist flutamide also had no effect on the activation of astrocytes induced by BPA. Furthermore, E₂ had no effect on the activation of astrocytes in both purified astrocytes and neurone/glia cocultures. It appears likely that oestrogen receptors and other steroid hormone receptors may not be critical for the activation of astrocytes induced by BPA. We also found that prenatal and postnatal *in vivo* exposure to E₂ failed to enhance the rewarding effect of morphine in mice. These data suggest that oestrogenic neurotransmission is not essential for the enhancement of dopaminergic neurotransmission and hypersensitivity to the morphine-induced rewarding effect induced by exposure to BPA.

In conclusion, the results of the present study suggest that BPA induces dopaminergic amplification in neurones and astrocytes, and may contribute to potentiate the development




Fig. 5. The effect of ICI182,780 on astrocytic activation induced by bisphenol-A (BPA). Mouse purified midbrain astrocytes (A) or neurone/glia cocultures (B) were treated with normal medium (control) or ICI182,780 (100 nM, 1 µM or 2 µM) for 24 h. Cells were then treated with normal medium, BPA (1 pM or 1 µM) with or without ICI182,780 (100 nM, 1 µM or 2 µM) for an additional 24 h. The cells were stained with a polyclonal antibody to glial fibrillary acidic protein (GFAP). The intensity of GFAP-immunoreactivity was measured using NIH Image. The level of GFAP-like immunoreactivity is expressed as a percent increase (mean ± SEM) with respect to that in control cells. ***P < 0.001 versus control cells. The white bars indicate the levels of GFAP-like immunoreactivity in the cells treated without BPA. The black bars indicate the levels of GFAP-like immunoreactivity in the cells treated with BPA. The grey bars indicate the levels of GFAP-like immunoreactivity in cells treated with BPA and ICI182,780.




FIG. 6. Effects of steroid hormone ligands on astrocytic activation induced by bisphenol-A (BPA). Mouse purified midbrain astrocytes (A–C) or mouse midbrain neurone/glia cocultures (D–F) were treated with normal medium or tamoxifen (100 nM, 1 μM or 10 μM; A,D), mifepristone (100 nM, 1 μM or 10 μM; B,E) or flutamide (100 nM, 1 μM or 10 μM; C,F) for 24 h. Cells were then treated with normal medium, or medium that had been supplemented with BPA (1 pM, 1 μM) with or without tamoxifen (100 nM, 1 μM or 10 μM; A,D), mifepristone (100 nM, 1 μM or 10 μM; B,E) or flutamide (100 nM, 1 μM or 10 μM; C,F) for an additional 24 h. The cells were stained with a polyclonal antibody to glial fibrillary acidic protein (GFAP). The intensity of GFAP-immunoreactivity was measured using NIH Image. The level of GFAP-like immunoreactivity is expressed as a percent increase (mean ± SEM) with respect to that in control cells. ***P < 0.001 versus control cells (without BPA or any antagonists). The black bars indicate the levels of GFAP-like immunoreactivity in cells treated without BPA. The white bars indicate the levels of GFAP-like immunoreactivity in cells treated with bisphenol-A. The grey bars indicate the levels of GFAP-like immunoreactivity in cells treated with bisphenol-A and steroid hormone ligands.

of the rewarding effect of morphine. Drug abuse among the young is increasing worldwide. On the other hand, emotional fragility often plays a major role in leading people to drug abuse. Our findings warn that prenatal and postnatal

exposure to BPA may be linked to severe health problems in humans, including abnormalities in the CNS, resulting in an emotional sensitivity toward the development of dependence on drugs of abuse.